Published in final edited form as:

Org Lett. 2009 July 2; 11(13): 2828–2831. doi:10.1021/ol900997t.

Syntheses and Biological Activity Studies of Novel Sterol Analogs from Nitroso Diels-Alder Reactions of Ergosterol

Baiyuan Yang^a, Patricia A. Miller^a, Ute Möllmann^b, and Marvin J. Miller^{a,*}

^a Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556

^b Leibniz Institute for Natural Products Research and Infection Biology – Hans Knoell Institute, Beutenbergstr. 11a, D-07745 Jena, Germany

Abstract

A series of novel sterol analogs was prepared using nitroso Diels-Alder reactions with ergosterol. Most cycloaddition reactions proceeded in an excellent regio- and stereoselective fashion. Further N-O bond cleavage of cycloadducts generated compounds with biological activity in PC-3 and MCF-7 cancer cell lines.

Natural products and their derivatives represent the most prolific source of molecular diversity in drug discovery.¹ Functional-group transformation of natural products constitutes one of the main avenues for generating pharmacologically relevant compounds with altered and sometimes improved biological properties. Typical chemical derivatizations of natural products are often limited to standard modification of nucleophilic or electrophilic functional groups. Since many natural products contain multiple functional groups of the same or similar type, derivatization selectivity is often problematic. Hence, new derivatization methods are still needed. Our effort in this area has involved nitroso Diels-Alder (NDA) reactions as efficient methods for derivatization and functionalization of diene-containing natural products. We and others² have demonstrated that many complex diene-containing natural products readily undergo nitroso cycloadditions, generating 1-amino-4-hydroxy-2-ene heterocycle scaffolds with high regio- and stereoselectivity. Ergosterol (Figure 1), a natural sterol containing a conjugated diene was chosen for further exploration of this method for modular enhancement of Nature's diversity (MEND).^{2a} Ergosterol **1a** (ergosta-5,7,22-trien-3 β -ol) is biologically relevant as a precursor (a provitamin) to Vitamin D₂ and an integral component of fungal cell membranes. The presence of ergosterol in fungal cell membranes coupled with its absence in animal cell membranes makes it a useful target for antifungal drugs.⁴ Several groups have shown that sterols with a hetero-atom substituent at C-24 or C-25 are effective antifungal compounds.⁵ Nitroso Diels-Alder reactions with ergosterol acetate **1b** were reported by Kirby et. al.,^{2d-e} however, this method was never exploited as a tool for derivatization of sterol compounds and the dienophiles used were often limited to transient aroyl nitroso species. Herein we report the syntheses of novel C5 and C8 disubstituted sterol analogs using nitroso

mmiller1@nd.edu.

Supporting Information Available: Full experimental procedures, characterization data and copies of ¹H NMR and ¹³C NMR spectra, protocols of antibacterial and anticancer assay. This material is available free of charge via the internet at <http://pubs.acs.org>.

Diels-Alder reactions of ergosterol, and its acetate, with acyl- and iminonitroso agents, and wish to demonstrate the utility of this methodology in natural product derivatization by evaluation of their biological activity.

A series of hydroxamic acids **2a–e** was obtained by reaction of the corresponding methyl esters with hydroxylamine; ⁶ *N*-hydroxycarbamate **2f** was prepared from direct acylation of hydroxylamine with di-*tert*-butyl dicarbonate. Oxidation of compounds **2a–f** to acyl nitroso dienophiles **3a–f** with tetrabutylammonium periodate in the presence of ergosterol acetate **1b** gave the 5 α *N*-8 α *O*-adducts **4a–f** in various yields (Scheme 1, Table 1). The stereoisomeric configuration of **4a–f** was assigned by ¹H NMR studies based on literature analysis of **4a**.^{2d} In the case of benzohydroxamic acid **2a** (entry 1, Table 1), similar to Kirby's observation,^{2d} dioxazine **6a** was isolated as the major product in 54% yield, with adduct **4a** as the minor product in 29% yield. Compound **6a** was formed as a result of [3, 3] sigmatropic rearrangement of 5 α *O*-8 α *N*-adduct **5a**, a much more sterically congested isomer compared to adduct **4a**.^{2d} Reaction with 4-methylbenzohydroxamic acid **2b** gave a similar result, although dioxazine **6b** was only isolated as a mixture with adduct **5b** (entry 2). In contrast, oxidation of 2-methoxybenzohydroxamic acid **2c**, phenylacetohydroxamic acid **2d**, L-leucine-derived hydroxamic acid **2e** and *tert*-butyl *N*-hydroxycarbamate **2f** gave **4c–f** as the sole products in good to excellent yields (entry 3–6). Further K₂CO₃ mediated deacetylation of **4a–f**, **6a** gave compounds **7a–f** and **8a** in 90% average isolated yields.

A nitroso Diels-Alder reaction with ergosterol **1a** was also investigated using nitrosobenzene **8** as a representative aryl nitroso dienophile (entry 1, Scheme 2). The NDA reaction occurred based on TLC and ¹H NMR analysis; however, adduct **11** was not able to be isolated in pure form by chromatography. Additionally, cycloadditions with various iminonitroso agents **10**, mainly 2-nitrosopyridine derivatives, were examined (Scheme 2). Those nitroso compounds were prepared from aminoheterocyclic precursors **9** in a two-step sequence (*N*, *N*-dimethyl sulfilimine intermediate formation, followed by oxidation using *m*-CPBA).⁷ Most of the iminonitroso compounds could be isolated and stored in pure form, except for **10k**. The NDA reactions between ergosterol **1a** and iminonitroso species **10a–j** usually were complete within 30 min at 0 °C. In each case, the cycloadducts **11a–j** were obtained as single 5 α *O*-8 α *N*-adducts in good to excellent yields after column chromatography (Scheme 2). The regio- and stereochemistry of the adducts was assigned based on our previous report and NMR studies.^{2a} The instability of nitroso agent **10k** required its immediate use, so it was trapped *in situ* with ergosterol acetate **1b**. Interestingly, both regioisomers **11k** and **11l** were obtained in a 8.5:1 ratio in 95% combined yield (entry 12, Scheme 2). The major adduct **11k** has the same stereochemistry as cycloadducts **11a–j**, based on X-ray crystallography (Figure 2). Further deacetylation of **11k** generated compound **11m**. Clearly, 2-nitrosopyridines **10**, as stabilized forms of iminonitroso reagents, constitute an ideal combination of reactivity and stability for NDA reactions with ergosterol, relative to benzenenitroso **8** and acylnitroso moieties **3**, respectively.

We next set out to demonstrate the synthetic utility of ergosterol nitroso cycloadducts through N-O bond cleavage, a method for generating 1,4-amino alcohols suitable for further diversification. Adduct **11a** was chosen as model for optimizing reaction conditions. Reactions with SmI₂/THF,⁸ Zn/CH₃COOH, Mo(CO)₆,⁹ etc. were attempted; however, all of these conditions failed to yield desired product **12a** (supporting information). Detailed screenings showed that Na amalgam¹⁰ successfully reduced the N-O bond of **11a** to give **12a** in 82% yield (entry 1, Scheme 3). Then, a series of ergosterol nitroso adducts was subjected to the optimized Na(Hg) conditions. While low transformation was found with acylnitroso adducts **7d** and **7f** (entries 2–3), moderate yields were achieved for pyridinylnitroso adducts. Not surprisingly, these conditions also reduced the -Cl substituent (entries 5–6).

Ergosterol peroxide **13** is a natural sterol derivative that possesses a variety of biological properties including immunosuppressive and antitumor activity. Simply removing the *N*-Boc group of cycloadduct **7f** afforded a quick access to compound **14** as an isoelectronic analog of ergosterol peroxide **13** (Scheme 4).

Broad antibacterial testing of these novel sterol analogs using the agar diffusion method revealed no significant activity against Gram-positive or Gram-negative organisms. However, N-O cleaved analogs had their largest zone of inhibition against the fungal strain, *Sporobolomyces salmonicolor*, whereas ergosterol, **1a**, and adducts did not (supporting information). More interestingly, N-O reduced compounds **12**, **12a–b,e,h,j**, along with ergosterol acylnitroso adducts **7a–f**, showed growth inhibitory activity in MCF-7 (breast cancer) and PC-3 (prostate cancer) tumor cell assays, while parent ergosterol, **1a**, and most pyridinylnitroso adducts were relatively inactive (entries 1, 9, 10, 12, 14–16, Table 2). All N-O reduced analogs reached the low micromolar range of inhibition against both PC-3 and MCF-7 cells (entries 17–22). In general, all active compounds showed significantly improved inhibitory activity against the MCF-7 cell line. These biological assays clearly suggest that the nitroso heterocycle changed the biological activity profile of its parent natural product.

In summary, we have reported that nitroso Diels-Alder reactions between ergosterol (or ergosterol acetate) and 2-nitrosopyridines as well as acylnitroso agents proceeded with excellent regio- and stereoselectivity. A new class of sterol analogs that show encouraging anticancer activity was generated through N-O bond cleavage of the cycloadducts. The method presented herein provides a novel and efficient way to derivatize diene-containing natural products. Efforts to determine the exact mechanism of anticancer action and further diversification of ergosterol adducts are in progress.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We acknowledge NIH (GM075885) for support of this research. We also thank Timothy Wenciewicz (UND) and Uta Wohlfield (HKI) for performing antibacterial assays, the NMR facility at Notre Dame, Dr. Allen Oliver (UND) for X-ray crystallography, Nonka Sevova (UND) for mass spectroscopic analyses. B.Y.Y acknowledges a Reilly Graduate Fellowship (2008–2009, UND).

References

1. (a) Butler MS. Nat Prod Rep 2005;22:162. [PubMed: 15806196] (b) Newman DJ, Cragg GM, Snader KM. J Nat Prod 2003;66:1022. [PubMed: 12880330]
2. (a) Li FZ, Yang BY, Miller MJ, Zajicek J, Noll BC, Mollmann U, Dahse HM, Miller P. Org Lett 2007;9:2923. [PubMed: 17602642] (b) Krchnak V, Waring KR, Noll BC, Moellmann U, Dahse HM, Miller MJ. J Org Chem 2008;73:4559. [PubMed: 18489157] (c) Ruan BF, Pong K, Jow F, Bowlby M, Crozier RA, Liu D, Liang S, Chen Y, Mercado ML, Feng XD, Bennett F, Schack DV, McDonald L, Zaleska MM, Wood A, Reinhart PH, Magolda RL, Skotnicki J, Pangalos MN, Koehn FE, Carter GT, Abou-Gharbia M, Graziani EI. Proc Natl Acad Sci USA 2008;105:33. [PubMed: 18162540] (d) Kirby GW, Mackinnon JWM. J Chem Soc, Perkin Trans 1;1985:887. (e) Kirby GW, Mackinnon JWM. J C S Chem Commun 1977;1:23. (f) Kirby GW, Bentley KW, Horwood P, Singh S. J Chem Soc, Perkin Trans 1;1979:3064. (g) Kirby GW, Sweeny JG. Chem Commun 1973:704.
3. Rajakumar K, Greenspan SL, Thomas SB, Holick MF. Am J Public Health 2007;97:1746. [PubMed: 17761571]
4. (a) Keith BB, Graham D. Acta Biochimica Polonica 1995;42:465. [PubMed: 8852337] (b) Walsh TJ, Viviani MA, Arathoon E, Chiou C, Ghannoum M, Groll AH, Odds FC. Med Mycology 2000;38:335.

5. (a) Nes WD, Guo D, Zhou W. Arch Biochem Biophys 1997;342:68. [PubMed: 9185615] (b) Ator MA, Schmidt SJ, Adams JL, Dolle JM, Kruse RE, Frey LI, Barone CL. J Med Chem 1992;35:100. [PubMed: 1732516] (c) Acuna-Johnson AP, Oehlschlager C, Pierce AM, Pierce HD Jr, Czyzewska EK. Bioorg Med Chem 1997;5:821. [PubMed: 9208094] (d) Beuchet P, Dherbomez M, Elkiel L, Charles G, Letourneux Y. Bioorg Med Chem Lett 1999;9:1599. [PubMed: 10386943]
6. Miller MJ, Biswas A, Krook MA. Tetrahedron 1983;39:2571.
7. (a) Taylor EC, Tseng CP, Rampal JB. J Org Chem 1982;47:552. (b) Sharma AK, Swern D. Tetrahedron Lett 1974;16:1503.
8. Revuelta J, Cicchi S, Brandi A. Tetrahedron Lett 2004;45:8375.
9. Cicchi S, Goti A, Brandi A, Guarna A, De Sarlos FD. Tetrahedron Lett 1990;31:3351.
10. Keck GE, Fleming S, Nickell D, Weider P. Syn Commun 1979;9:281.
11. (a) Bok JW, Lerner L, Chilton J, Klingeman HG, Towers GHN. Phytochem 1999;51:891. (b) Kim DS, Baek NI, Oh SR, Jung KY, Lee IS, Kin JK, Lee HK. Arch Pharm Res 1997;20:201. [PubMed: 18975152]

Figure 1.
Ergosterol (**1a**) and ergosterol acetate (**1b**)

Figure 2.
X-ray of cycloadduct **11k** with ergosterol acetate **1b**

Scheme 1.

^a **11** was failed to be isolated through silica gel chromatography.

^b 1.2 equiv of nitroso was used. ^c ergosterol acetate **1b** was used.

Scheme 2.

entry	adduct	product	R (product)	yield (%)
1	11a	12a		82
2	7d	12		26
3	7f	-		trace
4	11b	12b		61
5 ^a	11e	12e + 12b		60 (1:3)
6 ^b	11h	12h		59
7	11m	12m		63

^a -Cl of R was partially reduced. ^b -Cl of R was fully reduced.

Scheme 3.

Scheme 4.

Table 1

Results of acylnitroso Diels-Alder reactions

entry	compd	adduct	yield (%)	dioxazine	yield (%)
1	2a	4a	29	6a	54
2	2b	4b	12	6b	63 ^a
3	2c	4c	74	6c	0 ^b
4	2d	4d	95	6d	0 ^b
5	2e	4e	93	6e	0 ^b
6	2f	4f	93	6f	0 ^b

^a as a nonseparable mixture of dioxazine **6b** and 5a*O*-8a*N*-adduct **5b**.

^b not detected.

Table 2

Results of anticancer screenings^a

entry	compd	% inhibition at 20 μ M			IC ₅₀ (μ M)	
		PC-3	MCF-7		PC-3	MCF-7
1	1a	10	15		-	-
2	7a	64	97		-	14
3	7b	40	97		16	14
4	7c	94	97		11	6
5	7d	76	96		12	14
6	7e	57	95		12	8
7	7f	73	89		17	20
8	14	48	82		>20	>20
9	11a	<10	15		-	-
10	11b	15	29		-	-
11	11c	76	100		-	15
12	11d-e, g-h	<10	<10		-	-
13	11i	22	90		-	17
14	11j	15	<10		-	-
15	11k	15	29		-	-
16	11m	8	20		-	-
17	12	94	94		9	6.5
18	12a	100	100		6	2
19	12b	100	100		6	3.5
20	12e	100	100		7	3
21	12h	100	100		10	2.5
22	12j	100	100		4	2.5

^aTrichostatin A was used as the positive control (MCF-7 IC₅₀ = 16 nM, PC-3 IC₅₀ = 160 nM).